Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/146685| Title: | Adverse reactions to Ginkgo biloba medicinal products released in European countries |
| Authors: | Ammendolia, Ilaria Attard, Everaldo Currò, Mariaconcetta Midiri, Paola Attard, Tamara Mannucci, Carmen Esposito, Emanuela Calapai, Gioacchino Cardia, Luigi Calapai, Fabrizio |
| Keywords: | Ginkgo -- Therapeutic use Herbs -- Therapeutic use Pharmacovigilance Drug monitoring Drugs -- Side effects Drugs -- Analysis |
| Issue Date: | 2025 |
| Publisher: | John Wiley & Sons Ltd. |
| Citation: | Ammendolia, I., Attard, E., Mannucci, C., Esposito, E., Calapai, G., Currò, M.,... & Calapai, F. (2025). Adverse Reactions to Ginkgo biloba Medicinal Products Released in European Countries. Phytotherapy Research 39(5), 2197-2201. |
| Abstract: | Dear Editor, Ginkgo biloba leaf extracts exhibit antioxidant, anticancer, antibacterial, antiviral, anti- inflammatory, and neuroprotective properties (Gohil et al. 2000). In Europe, according to the European Directive 24/2004 (Chinou 2014), European Medicines Agency (EMA) approved Ginkgo biloba extracts in 2015 as a medicinal product “for the improvement of cognitive deterioration associated with age and quality of life in mild dementia” and for the “relief of the feeling of heaviness in the legs and circulatory disorders characterized by the sensation of cold in the hands and feet” (European Medicines Agency Science Medicines Health 2015). [extract]. |
| URI: | https://www.um.edu.mt/library/oar/handle/123456789/146685 |
| Appears in Collections: | Scholarly Works - InsESRSF |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Adverse_reactions_to_Ginkgo_biloba_medicinal_products_released_in_European_countries_2025.pdf | 274.68 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.